Triple combination therapy kills glioblastoma in mice by putting an “eat me” signal to the immune system on the surface of the brain tumor cells, blocking an offsetting “don’t eat me” signal and protecting a cancer-killing immune response launched by the combination.
The brain tumor treatment, as reported in Nature Communications, more than doubled median survival of mice treated with all three drugs, compared to those treated...
Glioblastoma is the most common, aggressive and deadly form of brain
cancer. Median overall survival for primary glioblastoma is 14.6
months with the standard treatments of surgery, radiation therapy and
the chemotherapy temozolomide, and falls to 5.5 – 11 months for
Tumor heterogeneity and the blood-brain barrier make it difficult to treat glioblastoma. Immunotherapies such as immune checkpoint inhibitors...